- Home
- XGN vs GALT Comparison
XGN vs GALT Comparison
Compare XGN & GALT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- XGN
- GALT
- Stock Information
- Founded
- XGN 2002
- GALT 2000
- Country
- XGN United States
- GALT United States
- Employees
- XGN N/A
- GALT N/A
- Industry
- XGN Medical Specialities
- GALT Biotechnology: Pharmaceutical Preparations
- Sector
- XGN Health Care
- GALT Health Care
- Exchange
- XGN Nasdaq
- GALT Nasdaq
- Market Cap
- XGN 210.4M
- GALT 232.3M
- IPO Year
- XGN 2019
- GALT N/A
- Fundamental
- Price
- XGN $11.04
- GALT $5.05
- Analyst Decision
- XGN Strong Buy
- GALT Strong Buy
- Analyst Count
- XGN 5
- GALT 3
- Target Price
- XGN $12.40
- GALT $6.00
- AVG Volume (30 Days)
- XGN 258.8K
- GALT 276.6K
- Earning Date
- XGN 11-11-2025
- GALT 11-12-2025
- Dividend Yield
- XGN N/A
- GALT N/A
- EPS Growth
- XGN N/A
- GALT N/A
- EPS
- XGN N/A
- GALT N/A
- Revenue
- XGN $58,862,000.00
- GALT N/A
- Revenue This Year
- XGN $22.28
- GALT N/A
- Revenue Next Year
- XGN $14.03
- GALT N/A
- P/E Ratio
- XGN N/A
- GALT N/A
- Revenue Growth
- XGN 3.89
- GALT N/A
- 52 Week Low
- XGN $2.38
- GALT $0.73
- 52 Week High
- XGN $11.28
- GALT $6.55
- Technical
- Relative Strength Index (RSI)
- XGN 64.51
- GALT 69.16
- Support Level
- XGN $10.63
- GALT $4.56
- Resistance Level
- XGN $11.28
- GALT $4.84
- Average True Range (ATR)
- XGN 0.38
- GALT 0.31
- MACD
- XGN -0.00
- GALT 0.02
- Stochastic Oscillator
- XGN 80.41
- GALT 76.80
About XGN Exagen Inc.
Exagen Inc is a commercial-stage diagnostics company committed to addressing the unmet need for the accurate diagnosis and monitoring of patients affected by autoimmune rheumatic diseases. It currently markets ten testing products under its Avise brand to provide an accurate, timely, and differential diagnosis and to optimize the treatment of ARDs. It markets and sells solutions to community rheumatologists.
About GALT Galectin Therapeutics Inc.
Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company. The company focuses on drug research and development to create new therapies for fibrotic disease, cancer, and selected other diseases. Its galectin-3 inhibitor is belapectin (GR-MD-02), which has been demonstrated in preclinical models to reverse liver fibrosis and cirrhosis.